


Product Name : CCT241736
Cat. No. : PC-24959
CAS No. : 1402709-93-6
Molecular Formula : C₂₂H₂₃Cl₂N₇
Molecular Weight : 456.38
Target : FLT3
Solubility : 10 mM in DMSO



CAS: 1402709-93-6

Biological Activity

CCT241736 (Mobinitinib) is a potent, orally bioavailable dual FLT3/Aurora kinase inhibitor with binding K_d of 7.5/48/6.2/38/14 nM for Aurora-A/Aurora-B/FLT3 WT/FLT3-ITD/FLT3(D835Y) respectively.

CCT241736 (Mobinitinib) shows S(10) selectivity score of 0.057 in a 442-kinase panel (containing 386 nonmutant kinases) at a concentration of 1 μM using the KINOMEScan technology.

CCT241736 (Mobinitinib) displays antiproliferative activity in a range of human tumor cell lines, including HCT116 human colon carcinoma (GI₅₀ = 0.300 μM) and the human FLT3-ITD positive AML cell lines MOLM-13 (GI₅₀ = 0.104 μM) and MV4-11 (GI₅₀ = 0.291 μM). inhibited both the autophosphorylation of Aurora-A at T288 (a biomarker for Aurora-A inhibition: IC₅₀ = 0.030 μM) and histone H3 phosphorylation at S10 (a biomarker for Aurora-B inhibition: IC₅₀ = 0.148 μM) in HeLa cells.

CCT241736 (Mobinitinib) (50-100 mg/kg po b.i.d.) significantly inhibits the growth of MV4-11 human FLT3-ITD positive AML tumor xenografts in athymic mice.

References

Wood FL, et al. Eur J Pharm Sci. 2019 Nov 1;139:104899.
 Bavetsias V, et al. J Med Chem. 2012 Oct 25;55(20):8721-34.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com